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Abstract
Background: Risk prediction tools are lacking for patients with stable disease some
years after myocardial infarction (MI).
Hypothesis: A practical long-term cardiovascular risk index can be developed.
Methods: The long-Term rIsk, Clinical manaGement and healthcare Resource utiliza-
tion of stable coronary artery dISease in post-myocardial infarction patients prospec-
tive global registry enrolled patients 1 to 3 years post-MI (369 centers; 25 countries),
all with ≥1 risk factor (age ≥65 years, diabetes mellitus requiring medication, second
prior MI, multivessel coronary artery disease, or chronic non-end-stage kidney dis-
ease [CKD]). Self-reported health was assessed with EuroQoL-5 dimensions. Multi-
variable Poisson regression models were used to determine key predictors of the
primary composite outcome (MI, unstable angina with urgent revascularization [UA],
stroke, or all-cause death) over 2 years.
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Results: The primary outcome occurred in 621 (6.9%) of 9027 eligible patients: death
295 (3.3%), MI 195 (2.2%), UA 103 (1.1%), and stroke 58 (0.6%). All events accrued
linearly. In a multivariable model, 11 significant predictors of primary outcome (age
≥65 years, diabetes, second prior MI, CKD, history of major bleed, peripheral arterial
disease, heart failure, cardiovascular hospitalization (prior 6 months), medical manage-
ment (index MI), on diuretic, and poor self-reported health) were identified and com-
bined into a user-friendly risk index. Compared with lowest-risk patients, those in the
top 16% had a rate ratio of 6.9 for the primary composite, and 18.7 for all-cause
death (overall c-statistic; 0.686, and 0.768, respectively). External validation was per-
formed using the Australian Cooperative National Registry of Acute Coronary Care,
Guideline Adherence and Clinical Events registry (c-statistic; 0.748, and 0.849,
respectively).
Conclusions: In patients >1-year post-MI, recurrent cardiovascular events and deaths
accrue linearly. A simple risk index can stratify patients, potentially helping to guide
management.
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1 | INTRODUCTION
Many low-risk patients with stable coronary disease following myo-
cardial infarction (MI) continue to live unencumbered by recurrent
cardiovascular events, while high-risk patients may benefit from more
intensive medical therapy.
Established risk scores exist for patients with MI both from
admission1,2 and from discharge,3,4 but risk prediction tools for
longer-term management of patients with stable disease following MI
are lacking. The long-Term rIsk, clinical manaGement and healthcare
Resource utilization of stable coronary artery dISease in post-
myocardial infarction patients (TIGRIS) prospective registry evaluated
a large representative group of patients recruited 1 to 3 years
post-MI.5
Given the recent availability of new therapies that can improve
outcomes in these patients,6-8 there is a need to understand the
drivers of risk in this cohort so as to identify those at greatest
absolute risk who are likely to sustain the greatest absolute
benefit.
This article focuses on incidence of the composite primary
endpoint (MI, unstable angina requiring revascularization, stroke,
and all-cause death) over 2 years, and characterizes any influence
by baseline patient factors. Our goal was to develop a user-friendly
risk index incorporating readily available items, see how strongly it
facilitated risk discrimination for the primary endpoint and for all-
cause death, and validate against an external population. Finally,
we discuss how this risk index may be used in patients with stable
coronary disease to determine those with relatively good progno-
sis and those at higher risk who may benefit from more intensive
management.
2 | HYPOTHESIS
That a practical cardiovascular risk index could be developed using
data from a global registry of patients >1 year post-MI, followed up
for 2 years.
3 | METHODS
3.1 | Study design and patients
TIGRIS is a prospective, global registry of patients enrolled 1 to
3 years post-MI in 25 countries in Europe, North America, Latin
America, Asia, and Australia, followed for 2 years. The study design
and patient characteristics have been described.5,9 Eligible patients
had at least one of the following: age ≥65 years, diabetes mellitus
requiring medication, a second prior MI, angiographic evidence of
multivessel disease, and chronic non-end-stage renal dysfunction.
TIGRIS was performed in accordance with ethical principles that
are consistent with the Declaration of Helsinki, the International Con-
ference on Harmonization Good Clinical Practice Guidelines, and
applicable legislation on nonintervention studies. All patients provided
written informed consent. The study protocol and informed consent
was reviewed and approved by the corresponding health authorities
and ethics boards for all participating study sites. This includes China
HGR approval of inclusion of 750 Chinese patients. The study was
registered at Clinical Trials.gov (clinical trial identifier NCT01866904).
Eligible patients who had survived an acute coronary syndrome
(ACS) were enrolled at discharge from participating centers and subse-
quently contacted every 6 months by phone or at study sites to
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ascertain outcome events and changes in medications. All outcome
events reported by patients and relatives (eg, hospitalizations, cardio-
vascular events, deaths) were confirmed by the study sites.
3.2 | Risk index development
The predefined primary composite endpoint of MI, unstable angina
with urgent revascularization (UA), stroke, and all-cause death showed
a linear accumulation of events over time.10 Hence, incidence of the
primary outcome by baseline variables was reported as rate per
100 patient-years. Poisson regression models simultaneously esti-
mated the association of several baseline variables with risk of events
expressed as incidence rate ratios (IRRs) and 95% confidence
intervals.
We used forward stepwise variable selection to derive a prelimi-
nary multivariable predictive model for risk of the primary outcome.
The five high-risk eligibility criteria were forced into this model, as
were sex and geographic region. All other variables needed to achieve
P < .05 for inclusion. A final condensed Poisson model for the primary
endpoint was obtained by only including variables significant at
P < .01, and by modeling age (<65 and ≥65 years) and diabetes as
binary variables.
To assess the risk impact of self-reported health, the 3-level
EuroQoL-5 dimensions (EQ-5D-3L) survey instrument11 was used.
Patients graded five dimensions (mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression) as no, moderate, or severe problem
scoring each as 0, 1, or 2 points, respectively, and summing to yield a
simple overall score (range 0-10). Recommended EQ-5D scorings such
as UK-weighted index12 are complex and impractical for clinical use.
The final predictive model was converted into an integer risk
index: variables with rate ratios ranging from 1.33 (congestive heart
failure) to 1.69 (prior major bleed) were each assigned 1 point, while
the strongest predictor EQ-5D-3L overall score ≥4 with rate ratio
2.06 was assigned 2 points.
This risk index was formed into six ordered categories from
0 points to ≥5 points. Risk discrimination was quantified using inci-
dence rates, IRRs using 0 points as reference, and Kaplan-Meier plots
over 2 years. Harrell's c-statistic summarized the strength of
discrimination.13
3.3 | External validation
External validation of the risk index used the Australian Cooperative
National Registry of Acute Coronary Care, Guideline Adherence and
Clinical Events (CONCORDANCE), which included 4672 post-MI
patients seen 6 months post-discharge.14 Occurrences of the primary
composite outcome and death were documented at 6 months
(n = 3197) or 18 months (n = 1451). Precise event dates were
unavailable with logistic regression used to predict outcomes,
adjusting for duration of follow-up. EQ-5D was missing in 1588
patients in CONCORDANCE. We therefore used multiple imputation
using five imputed datasets, combining results using Rubin's rules15;
predictor variables were the primary outcome, death, and other risk
model variables.
All statistical analyses used Stata version 15.1.
4 | RESULTS
4.1 | Patient characteristics
From June 2013 to November 2014, 9225 patients were enrolled;
median 1.8 years post-MI with at least one pre-defined risk factor.
From these, 9027 (97.9%) had baseline and follow-up data: age
≥65 years (5626 [62.3%] patients), diabetes mellitus requiring medica-
tion (3018 [33.4%]), a second prior MI (924 [10.2%]), multivessel dis-
ease (5941 [65.8%]), and chronic non-end-stage renal dysfunction
(691 [7.7%]). Patient characteristics recorded at enrollment and num-
bers enrolled by country are provided in Tables S1 and S2.
4.2 | Primary outcome
The primary outcome occurred in 621 (6.9%) from 9027 patients over
2 years, with all-cause death in 295 (3.3%), MI in 195 (2.2%), unstable
angina requiring revascularization in 103 (1.1%), and stroke in
58 (0.6%) patients.
For the primary outcome and components, a steady linear accu-
mulation of events occurred over time.10
4.3 | Identifying predictors of risk
Univariate associations of patient characteristics to the primary out-
come incidence rate are provided in Table S1, with IRRs shown both
unadjusted and adjusted for the five eligibility criteria, region, and
country. Unadjusted incidence rates by region and country are shown
in Table S2.
To identify which variables remained statistically significant inde-
pendent risk predictors in multivariable analyses, forward stepwise
variable selection was used to derive a preliminary predictive model
for risk of the primary outcome (Table 1). The influence of age is
effectively summarized by elevated risk for age ≥65 years. Diabetes is
an important risk predictor, particularly for insulin-treated patients, as
are having a second prior MI, a prior major bleed, peripheral arterial
disease, and prior heart failure. Also, cardiovascular hospitalization in
the last 6 months, medical management only for the index MI, and
diuretic therapy at enrollment also carried elevated risk.
The EQ-5D findings indicate the prognostic importance of
patient-reported heath status with each constituent item showing
increased univariate trends of risk from no-to-some-to-severe prob-
lems (Table S1). Their sum yielded an overall ED-5D-3L score ranging
from 0 (no problems on all five items) to 10 (severe problems on all
five items). An overall score of 3 has a significantly elevated risk,
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which increased further for a score of ≥4 (Table 1). The EQ-5D visual
analog score did not independently predict risk.
Sex, multivessel disease, and region were not statistically signifi-
cant independent predictors. Patients on single antiplatelet therapy at
enrollment appeared to have a lower risk. The underlying selection
processes are unknown so this factor was not considered further. Var-
iables expected to predict risk (eg, low blood pressure, elevated heart
rate) were not independent predictors.
4.4 | Final predictive model
A final refined predictive model for the primary outcome is shown
in Table 2, including 11 yes/no items independently contributing
highly significant IRRs ranging from 1.33 to 1.69. For EQ-5D over-
all score, values of 3 and ≥4 contributed IRRs of 1.47 and 2.06,
respectively.
To make this prediction model more user-friendly, we propose
a risk index for each patient (Table 2). All items contributed 1 point
to the risk index, except for EQ-5D overall score ≥4 (2 points). Dis-
tribution of the risk index for 8978 patients with complete infor-
mation is shown in Figure S1. A value of 0 points occurred in 12%
of patients, 1 point was most common (33% of patients), followed
by a skewed distribution to a maximum of 10 points in four
patients.
Figures 1A and 2A show a marked trend in risk of the primary
outcome. Compared to 0 points, IRRs ranged from 1.34 for 1 point
to 4.54 and 9.79 for those with 4 and ≥5 points, respectively. To
assess goodness of fit of the model, we compared the observed
and predicted rates for the primary outcome across risk index cate-
gories (see Figure S2). Figure 2A shows cumulative incidence of
the primary outcome by categories of the risk index, revealing mar-
ked separation in risk. The 2-year cumulative incidence for the pri-
mary outcome ranged from 2.8% for 0 points up to 11.9% and
23.7% for 4 and ≥5 points, respectively. For all-cause death, com-
pared to patients with 0 points, there is an even steeper risk gradi-
ent (IRR) ranging from 1.77 for 1 point to 11.19 and 27.61 for
4 and ≥5 points, respectively (Figures 1 and 2B). c-Statistics for
the risk index are 0.686 for the primary outcome and 0.768 for all-
cause death.
4.5 | External validation
External validation of this risk index was explored comparing TIGRIS
with the CONCORDANCE registry,14 comprising 4672 Australian
patients recruited 6-months post-MI. While primary outcome inci-
dence patterns are broadly similar, some differences exist regarding
baseline variables (Table S3). When applying the TIGRIS risk index to
CONCORDANCE, we observed similar, markedly steep gradients for
both the primary composite outcome and all-cause death (Figure 3).
c-Statistics for the primary outcome (c = 0.748) and all-cause death
(c = 0.849) are somewhat greater than in the TIGRIS population. It is
TABLE 1 Multivariable Poisson regression model for the risk of
the primary composite outcome (based on forward stepwise variable
selectiona)
Variable at enrollment
Rate ratio
(95% CI)
P
value
Age, years
<55 Reference group .030
55-59 1.02 (0.68, 1.53)
60-64 1.13 (0.77, 1.67)
65-69 1.49 (1.03, 2.14)
70-74 1.40 (0.97, 2.03)
75-79 1.54 (1.05, 2.25)
80+ 1.58 (1.05, 2.38)
Female 0.87 (0.72, 1.05) .15
Category of diabetes
No diabetes Reference group <.001
Non-insulin-treated diabetes 1.30 (1.07, 1.57)
Insulin-treated diabetes 1.71 (1.36, 2.15)
Second prior MI 1.45 (1.18, 1.80) <.001
Multi-vessel disease 1.14 (0.95, 1.37) .15
Chronic kidney disease 1.53 (1.22, 1.92) <.001
Major bleed 1.67 (1.21, 2.32) .002
Peripheral arterial disease 1.45 (1.14, 1.84) .002
Congestive heart failure 1.30 (1.05, 1.60) .015
Cardiovascular event in past
6 months
1.39 (1.05, 1.84) .021
On diuretics at enrollment 1.57 (1.31, 1.88) <.001
Type of anti-thrombotic medication
SAPT Reference group .025
No APT 1.30 (0.97, 1.75)
DAPT 1.25 (1.04, 1.52)
Type of management of index MI
PCI Reference group <.001
CABG 0.79 (0.56, 1.11)
Medical only 1.58 (1.28, 1.95)
EQ-5D overall score (0–10)
0 Reference group <.001
1 1.14 (0.90, 1.43)
2 1.30 (1.01, 1.67)
3 1.61 (1.23, 2.12)
4+ 2.25 (1.76, 2.89)
Region
Asia and Australia Reference group .72
Europe 0.99 (0.70, 1.39)
North America 1.07 (0.64, 1.79)
Latin America 1.22 (0.80, 1.87)
Abbreviations: APT, antiplatelet therapy; CABG, coronary artery bypass
graft; CI, confidence interval; DAPT, dual antiplatelet therapy; EQ-5D,
EuroQol-5 dimensions; MI, myocardial infarction; PCI, percutaneous
coronary intervention; SAPT, single antiplatelet therapy.
aSex, region, and the five eligibility criteria were forced into the model.
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difficult to attribute a definitive cause for this. Notably, associations
for age, congestive heart failure, and cardiovascular events are stron-
ger in CONCORDANCE than TIGRIS. It follows, therefore, that the
presence of one of these characteristics will have a larger impact on
underlying risk in the former, making it easier to discriminate patients
(see Table S4). In addition, risk factors strongly associated with risk in
CONCORDANCE are also generally more common (medical manage-
ment, CV event in the prior 6 months). Thus, in general, patients are
more diverse in terms of the risk factors they present with, again facil-
itating easier discrimination.
TABLE 2 A refined predictive model for risk of the primary composite outcome and simplified scoring for the risk index
Variable Percentage of TIGRIS patients affecteda Rate ratio (95% CI) P value Contribution to risk indexb
Age ≥ 65 years 62.3 1.34 (1.12, 1.60) .001 1
Diabetes 33.4 1.42 (1.20, 1.67) <.001 1
Second prior MI 10.2 1.52 (1.24, 1.88) <.001 1
Chronic kidney disease 7.7 1.61 (1.29, 2.02) <.001 1
Heart failure 11.4 1.33 (1.08, 1.64) .008 1
Peripheral arterial disease 6.7 1.52 (1.20, 1.93) <.001 1
Cardiovascular event in past 6 months 4.8 1.46 (1.11, 1.93) .008 1
Prior major bleed 2.8 1.69 (1.22, 2.34) .002 1
Medical management only of index event 11.9 1.62 (1.33, 1.99) <.001 1
On diuretic at enrollment 25.1 1.62 (1.35, 1.93) <.001 1
EQ-5D overall scorec of 3 7.8 1.47 (1.15, 1.88) <.001 1
EQ-5D overall scorec ≥ 4 9.0 2.06 (1.67, 2.55) <.001 2
Abbreviations: CI, confidence interval; EQ-5D, EuroQol-5 dimensions; MI, myocardial infarction; TIGRIS, long-Term rIsk, Clinical manaGement and
healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients.
aAmong 8978 patients with complete information on covariates in the risk index.
bThe rate ratio for EQ-5D overall score ≥4 was 2.06 while the rate ratio for all other items ranged from 1.33 to 1.69. In the interests of practical simplicity,
2 points have been assigned to the former and 1 point to each of the others.
cThe EQ-5D grades five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) as no, moderate, or severe problem. Scoring
each as 0, 1, or 2 points, respectively, and adding these up yields an overall score ranging from 0-10. A score of 3 points means a patient had either: (a)
three dimensions with moderate problem or (b) one dimension with moderate problem and one dimension with severe problem. A score of 4 or more
points means a patient had at least either: (a) four dimensions with moderate problem; (b) two dimensions with moderate problem and one dimension with
severe problem; (c) two dimensions with severe problem.
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5 | DISCUSSION
In a global representative sample of patients 1 to 3 years post-MI with
≥1 risk factor, we have quantified what determines the truly high-risk
patient with stable coronary disease.
The 11 highly significant independent predictors, including
patient self-reported health status, are readily available in routine
clinical practice. Combining them into an integer risk index provides
an easy-to-use method of assessing individual post-MI risk of a major
cardiovascular event or death over 2 years.
There is marked variation in individual patient risk, ranging from
12.2% of patients with risk index 0 points (primary outcome incidence
rate of 1.4 per 100 patient-years) to 7.4% of patients with ≥5 points
(13.7 per 100 patient-years): IRR 9.8. The risk gradient for primary
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outcome is steep, whereby each added point contributed ≥30% extra
cumulative risk. For all-cause death, the gradient becomes steeper
with ≥75% extra cumulative mortality risk per point.
Independent contribution of increasing age is best captured by
age over 65 years with increased risk represented by increased sus-
ceptibility to comorbidities and poorer quality of life included sepa-
rately in the risk index.
Other concomitant conditions (diabetes, chronic kidney disease,
heart failure, peripheral arterial disease and >1 MI) all contribute to
increased risk. These likely reflect the greater burden of vascular dis-
ease in these patients. Having their MI medically managed only, and
history of major bleeding also contributed to increased risk, possibly
reflecting failure to tolerate or be offered prognostically important
therapies. All of these factors have contributed to other risk scores in
stable and unstable populations.3,4,16-18
A more innovative contributor to our risk index is patient self-
reported health status, using a simple overall score derived from the
EQ-5D-3L. Patients with poor self-reported health (3 points) had
around a 50% increase in cardiovascular incidence rate, while those
with very poor self-reported health (≥4 points) had around a doubling
of incidence rate (Table 2). This simple patient rating of health status
was the strongest contributor to risk. The EQ-5D instrument is also
reported as a strong predictor of mortality after discharge post-MI.3,4
The reasons for this are speculative; in some patients the EQ-5D may
be unmasking undetected depression, a known adverse marker of
poor prognosis,19 or it may be that patients with poorer self-reported
quality of life are less likely to adhere to prescribed medications, or to
attend cardiac rehabilitation, behaviors which have both been shown
to adversely affect long-term outcomes20,21
We also studied the UK-weighted index score for the EQ-5D-3L,
revealing results comparable to our easier-to-use overall score.
For external validation, we used the CONCORDANCE registry14
as it included all items in our risk index, and data on our primary out-
come. This Australian population had follow-up starting 6 months
after MI, so not a perfect match to our TIGRIS population. Neverthe-
less, the risk index achieves a broadly similar extent of risk discrimina-
tion for both the primary outcome and death. It is of considerable
practical value to be able to identify which patients with stable coro-
nary disease are at high risk of cardiovascular events and death. For
instance, there are important risk reductions with new therapies for
LDL-lowering6 and relating to antithrombotic therapy.7,8 Identifying
the spectrum of risk in stable patients eligible for such treatments will
identify those high-risk patients for whom the absolute reduction will
be greatest.
Reported risk models for patients with stable coronary disease
post-MI are sparse. Closest is perhaps the Reduction of
Atherothrombosis for Continued Health (REACH) Registry,22 which
included a mixed population comprising coronary heart disease, cere-
brovascular disease, and peripheral vascular disease. Their model for
predicting cardiovascular event risk over 20 months included 11 items
(six common to our risk index) but is dominated by increasing risk with
age. Applied to TIGRIS, the REACH score showed weaker discrimina-
tion: c-statistic 0.62 compared with 0.69 for ours.
Based on the Thrombin Receptor Antagonist in Secondary Pre-
vention of Atherothrombotic Ischemic Events (TRA 2P-TIMI 50)
trial,23 a multivariable risk model was derived for cardiovascular death,
MI, and ischemic stroke over a median 2.5 years in 8598 placebo-
treated patients recruited 2 weeks to 1-year post-MI. Their popula-
tion is earlier post-MI, with 45% recruited within 3 months and 74%
within 6 months.24 Thus, early follow-up is in the post-acute phase
when mortality is double that at 1-year post-MI.25 Their risk model
contains nine items, three of which (smoking, prior coronary artery
bypass graft, and hypertension) were not independent predictors
when applied to TIGRIS. Hence, applying the TIMI-50 risk model to
our population showed weaker discrimination: c-statistic 0.63 and
0.70 for the primary outcome and all-cause death, respectively. How-
ever, we acknowledge that the c-statistic for our own risk score may
be slightly optimistic, given that it is derived and assessed in the same
population.
Battes et al26 studied patients in the EURopean trial On reduction
of cardiac events with Perindopril in stable coronary Artery disease
(EUROPA) database: 65% had a prior MI ≥3 months beforehand. Their
risk models, over a median follow-up of 4.1 years, had 11 predictor
variables for cardiovascular death and a composite outcome including
MI and cardiac arrest; the c-statistics were 0.73 and 0.63, respec-
tively, a weaker prediction than we found. Rapsomaniki et al27 used
electronic health records for 102 023 patients with stable coronary
disease, 23% with prior MI ≥6 months ago. Their risk models over a
mean 4.4 years included 21 predictor variables for all-cause death and
the composite of coronary death and MI; c-statistics were 0.81 and
0.78, respectively. While these showed excellent predictive power,
model complexity may limit practical value. Clayton et al28 studied
7311 patients with stable angina in A Coronary disease Trial Investi-
gating Outcome with Nifedipine GITS (ACTION); 51% of whom had a
prior MI. Their risk model over a mean 4.9 years included 16 predictors
for a composite of all-cause death, MI, and stroke; again, complexity
may limit utility.
Regarding our study's limitations, based on 50 candidate predic-
tors, there is risk of “false positives” entering our risk model. However,
with P < .01 as entry criterion, risk is relatively low. The most novel
highly significant predictor is EQ-5D overall score, while other risk
index items are not surprising, having rational explanations based on
prior studies. One problem potentially affecting the widespread use of
our risk index may be that patients self-reported health status by EQ-
5D is not routinely collected in most clinical settings. This is an emerg-
ing concern given the recognition of the importance of patient
reported outcomes as indicators of the quality of care they receive.29
In showing that patient reported outcomes makes a clear contribution
to their prognosis, we provide additional justification for the impor-
tance of collection of data on patient symptom status and encourage
a wider appreciation that an assessment of patient self-perception of
their well-being is an important component of patient care.
While TIGRIS was designed to recruit representative patients in
representative centers in each country, we cannot verify a truly gen-
eralizable population. Also, TIGRIS recruitment required each patient
to have ≥1 of 5 risk criteria, four of which (all except multi-vessel
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coronary artery disease) are in the risk model. Thus, in applying our
risk index to an unselected population of patients, a higher proportion
may be identified as low risk.
We have successful external validation for our risk index using
the CONCORDANCE registry and would encourage further validation
studies in other relevant populations. While we studied patients rec-
ruited 1 to 3 years post-MI, it would be interesting to see how our risk
index performs in a broader class of patients with stable coronary
disease.
6 | CONCLUSION
We have described how risk of subsequent cardiovascular events and
death varies substantially among patients 1 to 3 years post-MI. A risk
index based on 11 readily available items enables stratification of such
patients into markedly different risk categories. Such knowledge could
help identify very high-risk patients in need of more intensive
management.
7 | DATA SHARING STATEMENT
Baseline patient characteristics and data on long-term oral antiplatelet
use and event rates in the TIGRIS registry have been published else-
where (all open access).5,9,10
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